Francine Foss, MD, reviews optimal management of a highly functional patient presenting with de novo tumor-stage mycosis fungoides.
Upon completion of this activity, participants should be able to:
Venetoclax Plus Rituximab Well Tolerated With Promising Activity in Patients With Relapsed/Refractory CLL
Ibrutinib Monotherapy Well Tolerated, Moderately Active in Patients With Relapsed or Refractory FL
In Patients With Relapsed CLL, Addition of Idelalisib to Rituximab Significantly Improved OS and Demonstrated Comparable Efficacy in Patients With and Without High-Risk Genetics
Brentuximab Vedotin Effective and Well Tolerated as First-line Salvage Treatment in Relapsed/Refractory HL Prior To Autologous HSCT
Fludarabine and Cyclophosphamide Plus Rituximab as Frontline Treatment for Fit CLL Patients Shows Higher Response and Longer Survival Compared With Bendamustine Plus Rituximab
Conference CoverageEducationClinicalThoughtDecision SupportCCO Live EventsSlidesets & Resources
Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
Clinical Care Options, LLC. All Rights Reserved.